Reply to: Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness

James C. Dickerson

James C. Dickerson, MD, MS, Jennifer L. Caswell-Jin, MD, and Fauzia Riaz, MD, MHS, Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA; and Jeremy D. Goldhaber-Fiebert, PhD, and Fernando Alarid-Escudero, PhD, Department of Health Policy, Stanford University, Stanford, CA

Jennifer L. Caswell-Jin

Fauzia Riaz

Stanford Cancer Institute, Stanford, CA

Jeremy D. Goldhaber-Fiebert

James C. Dickerson, MD, MS, Jennifer L. Caswell-Jin, MD, and Fauzia Riaz, MD, MHS, Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA; and Jeremy D. Goldhaber-Fiebert, PhD, and Fernando Alarid-Escudero, PhD, Department of Health Policy, Stanford University, Stanford, CA

Fernando Alarid-Escudero

James C. Dickerson, MD, MS, Jennifer L. Caswell-Jin, MD, and Fauzia Riaz, MD, MHS, Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA; and Jeremy D. Goldhaber-Fiebert, PhD, and Fernando Alarid-Escudero, PhD, Department of Health Policy, Stanford University, Stanford, CA